Washington, D.C. — In the aftermath of a deadly outbreak of acid refraction in the city, several local officials have begun to offer a new treatment for patients who are susceptible to the disease.

In recent weeks, a handful of doctors have started offering patients a new drug to help control acid refractive disorder, also known as acid refractory colitis, or ARC.

The drug is an antibiotic called carboplatin.

Patients with acid eye disease usually have to get help from a doctor, or have to go to an eye clinic.

Carboplatin has also been used to treat colitis in the past, and patients in some of those cases reported the drug helped relieve their symptoms, said Dr. Peter K. Sperling, a consultant in ophthalmology at Washington University in St. Louis.

But, this is the first time that doctors have offered it for patients.

“This is an extremely exciting treatment,” Sperlin said.

“It’s very exciting to have a drug that is going to help you for a long time.

This is the most promising drug to date.”

The drug has been approved for treating acid refractions, and doctors said patients could begin taking it by the end of the year.

The drugs work by blocking an enzyme in the blood that breaks down acid.

The medication is administered to patients over the course of a week.

The dosage varies based on the severity of the refraction problem, and is typically given as a single pill, or a single dose of the drug, about once a week, according to the FDA.

The FDA approved the drug in April for treating refractive disorders like ARC.

Dr. John J. Bierut, chief of the ophthalmic oncology unit at the University of Maryland in College Park, said he hopes to see the drug available by the beginning of 2018.

Biersut is also a consultant to the drug and has been working with the drug’s manufacturer, AstraZeneca, to prepare for its release.

“I am hoping we will have the drug out there by the first quarter of 2019, and hopefully it will be available by mid-year,” he said.

The FDA has not yet approved the medication for other types of refraction, but Biersuts hopes that it will.

He said it may not be the only treatment for acid refracted eye disease.

“If we have any indication that this drug could be useful, we will do a clinical trial, and we will follow up to see if it has any efficacy in treating other types,” he told The Washington Post.

Bieruts said he has seen the drug work in other refractive and colitis patients.

A study of 20 patients with acid, refractive, and colitic disorders published last month showed it was effective at relieving symptoms and improving eye function, he said, and that it has not had any side effects.

“The patients that we have seen have had a good response,” he added.

“It seems to work,” said Dr